We are monitoring the impact of COVID-19 on MEA Cancer Immunotherapy Market Get in touch with us for detailed analysis Know More
Share on

Middle East & Africa Cancer Immunotherapy Market Research Report – Segmented By Application, Product Type, Mode Of Administration, End Users, Country (KSA, UAE, Israel, rest of GCC countries, South Africa, Ethiopia, Kenya, Egypt, Sudan, rest of MEA) - Industry Analysis on Size, Share, Trends, COVID-19 Impact & Growth Forecast (2022 to 2027)

Published: January, 2022
ID: 1341
Pages: 132

MEA Cancer Immunotherapy Market Size (2022 to 2027)

The Cancer Immunotherapy Market size in Middle East & Africa is predicted to be growing at a CAGR of 11.35% from 2022 to 2027. The market size is predicted to be worth USD 9.21 billion by 2027 from USD 5.38 billion in 2022.

Cancer immunotherapy has emerged as a new avenue for revenue generation for pharmaceutical companies in Middle East Africa. In addition, the Increasing Access to medical insurance in developing countries such South Africa, UAE, and Saudi Arabia, is expected to impact the market growth positively.

The market for cancer immunotherapy in MEA is expected to be driven by the proliferation of cancer and growing awareness about cancer treatment among the people in the region. Also, there is a rising preference for immunotherapy over conventional techniques. This is because it provides long-term cancer protection, has more minor side effects, and treats a wide range of cancer populations. In addition, technological advancements in the healthcare sectors region, including advanced cancer treatment therapies, are expected to fuel the market growth.

The growing population is considered one of the major growth contributors to the market growth, as the rise in the population is vulnerable to various cancer diseases that are expected to drive the market. In addition, the initiatives taken by the government for creating awareness programs about the availability of cancer treatments are most likely to influence the market growth. Moreover, increasing investments and funding by the government and private organizations to develop healthcare infrastructure provides the way for new market entrants. Additionally, the major companies in the region are conducting research and development activities on cancer immunotherapy are providing lucrative growth opportunities for the market growth. 

Patients who have failed to react to chemotherapy have benefited from the introduction of novel compounds. In addition, several new immunotherapeutic alternatives, such as immunomodulators and CAR-T cell therapy, are being evaluated in the lab to see if they might improve cancer treatment; therefore, rising research and development activities are expected to encourage market growth. Furthermore, growing approvals for novel immunotherapy medicines for treating cancers such as prostate cancer, blood cancer, colorectal cancer, melanoma, breast cancer, lung cancer, and others are propelling the sector ahead. 

However, the stringent government regulations related to cancer immunotherapy are hindering market growth. In addition, the government has promoted monitoring of immunotherapy usage. It is also monitoring clinical trials conducted following government guidelines, making it more difficult for firms to enter the field and, as a result, likely to impede market growth.

This research report on the MEA Cancer Immunotherapy market has been segmented & sub-segmented into the following categories:

By Type of Therapies: 

  • Immune System Modulators
  • Immune Checkpoint Inhibitors
  • Monoclonal Antibodies

By Area of Therapy: 

  • Blood Cancer
  • Prostate Cancer
  • Melanoma
  • Breast Cancer
  • Lung Cancer
  • Colorectal Cancer
  • Other Minor Areas

By Country: 

  • KSA
  • UAE
  • Israel
  • rest of GCC countries
  • South Africa
  • Ethiopia
  • Kenya
  • Egypt
  • Sudan
  • rest of MEA

Geographically, the Middle East region is anticipated to record a considerable share in the MEA Cancer immunotherapy market during the forecast period. The market growth in the region is attributed to the increasing incidence of cancer patient pool, rising demand for cancer treatments, and adoption of modern therapeutics. In addition, the other factors, such as increasing healthcare expenditure and the rising number of ongoing clinical trials, are expected to promote market growth. Also, New and Advanced immunotherapy drugs have been introduced in the developed countries such as UAE, South Africa, and Saudi Arabia.

South Africa is expected to dominate the MEA Cancer immunotherapy market and account for the highest share in 2020. Cancer disease prevalence, high mortality rate, and favorable government policies are fuelling the market growth. Also, the availability of sophisticated immunotherapy medications is further expected to boost market growth. However, the market is projected to witness significant growth in the coming years.

On the other hand, countries like the United Arab Emirates and Saudi Arabia are most likely to showcase a promising share and contribute to the MEA regional market growth. The market is expected to grow as healthcare spending rises and reimbursement policies become more transparent. In addition, the rising prevalence of cancer has been a primary element driving the growth of the cancer immunotherapy market.

KEY MARKET PLAYERS:

A few of the noteworthy companies operating in the MEA cancer immunotherapy market profiled in this report are F. Hoffmann-La Roche Ltd, Amgen, Viralytics, Novartis Pharmaceuticals Corporation, Pfizer, GlaxoSmithKline Pharmaceuticals Limited, AstraZeneca plc, Medivation, Advaxis, Bristol-Myers Squibb, Merck & Co. and Celgene Corp and Immunomedics.

1.Introduction                                  

                1.1 Market Definition                    

                1.2 Study Deliverables                  

                1.3 Base Currency, Base Year and Forecast Periods                           

                1.4 General Study Assumptions                

2. Research Methodology                                           

                2.1 Introduction                              

                2.2 Research Phases                      

                                2.2.1 Secondary Research            

                                2.2.2 Primary Research 

                                2.2.3 Econometric Modelling     

                                2.2.4 Expert Validation  

                2.3 Analysis Design                         

                2.4 Study Timeline                          

3. Overview                                      

                3.1 Executive Summary                

                3.2 Key Inferences                         

                3.3 Epidemology                             

4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)                                      

                4.1 Market Drivers                          

                4.2 Market Restraints                    

                4.3 Key Challenges                         

                4.4 Current Opportunities in the Market               

5. Market Segmentation                                              

                5.1 Application                 

                                5.1.1 Introduction           

                                5.1.2 Breast       

                                5.1.3 Lung          

                                5.1.4 Melanoma              

                                5.1.5 Colorectal

                                5.1.6 Head & Neck          

                                5.1.7 Prostate   

                                5.1.8 Others      

                                5.1.9 Y-o-Y Growth Analysis, By Application         

                                5.1.10 Market Attractiveness Analysis, By Application     

                                5.1.11 Market Share Analysis, By Application      

                5.2 Product Type                             

                                5.2.1 Introduction           

                                5.2.2 Monoclonal Antibodies     

                                5.2.3 Checkpoint inhibitors/immune modulators              

                                5.2.4 Therapeutic cancer vaccines            

                                5.2.5 Oncolytic virus immunotherapy     

                                5.2.6 Cytokines

                                5.2.7 Adoptive T cell transfer     

                                5.2.8 Adjuvant Immunotherapy

                                5.2.9 Interferons             

                                5.2.10 Interleukins         

                                5.2.11 BCG         

                                5.2.12 Others   

                                5.2.13 Y-o-Y Growth Analysis, By Product Type   

                                5.2.14 Market Attractiveness Analysis, By Product Type

                                5.2.15 Market Share Analysis, By Product Type  

                5.3 Mode of Administration                        

                                5.3.1 Introduction           

                                5.3.2 Intravenous           

                                5.3.3 Oral            

                                5.3.4 Topical      

                                5.3.5 Intra Vesical           

                                5.3.6 Y-o-Y Growth Analysis, By Mode of Administration

                                5.3.7 Market Attractiveness Analysis, By Mode of Administration              

                                5.3.8 Market Share Analysis, By Mode of Administration

                5.3 End users                    

                                5.3.1 Introduction           

                                5.3.2 Hospitals  

                                5.3.3 Clinics        

                                5.3.4 Y-o-Y Growth Analysis, By End users            

                                5.3.5 Market Attractiveness Analysis, By End users           

                                5.3.6 Market Share Analysis, By End users            

6. Geographical Analysis                                              

                6.1 Introduction                              

                                6.1.1 Regional Trends    

                                6.1.2 Impact Analysis     

                                6.1.3 Y-o-Y Growth Analysis        

                                                6.1.3.1 By Geographical Area

                                                6.1.3.2 By Application

                                                6.1.3.3 By Product Type

                                                6.1.3.4 By Mode of Administration

                                                6.1.3.5 By End users

                                6.1.4 Market Attractiveness Analysis      

                                                6.1.4.1 By Geographical Area

                                                6.1.4.2 By Application

                                                6.1.4.3 By Product Type

                                                6.1.4.4 By Mode of Administration

                                                6.1.4.5 By End users

                                6.1.5 Market Share Analysis        

                                                6.1.5.1 By Geographical Area

                                                6.1.5.2 By Application

                                                6.1.5.3 By Product Type

                                                6.1.5.4 By Mode of Administration

                                                6.1.5.6 By End users

                6.2 Middle-East                                

                6.3 Africa                            

7.Strategic Analysis                                        

                7.1 PESTLE analysis                         

                                7.1.1 Political     

                                7.1.2 Economic 

                                7.1.3 Social         

                                7.1.4 Technological         

                                7.1.5 Legal          

                                7.1.6 Environmental      

                7.2 Porter’s Five analysis                              

                                7.2.1 Bargaining Power of Suppliers        

                                7.2.2 Bargaining Power of Consumers    

                                7.2.3 Threat of New Entrants     

                                7.2.4 Threat of Substitute Products and Services

                                7.2.5 Competitive Rivalry within the Industry      

8.Market Leaders' Analysis                                          

                8.1 F. Hoffmann-La Roche Ltd                    

                                8.1.1 Overview

                                8.1.2 Product Analysis   

                                8.1.3 Financial analysis  

                                8.1.4 Recent Developments       

                                8.1.5 SWOT analysis       

                                8.1.6 Analyst View          

                8.2 Amgen                         

                8.3 Viralytics                      

                8.4 Novartis Pharmaceuticals Corporation                            

                8.5 Pfizer                            

                8.6 GlaxoSmithKline Pharmaceuticals Limited                     

                8.7 AstraZeneca plc                        

                8.8 Medivation                

                8.9 Advaxis                        

                8.10 Bristol-Myers Squibb                           

                8.11 Merck & Co. and Celgene Corp                        

                8.12 Immunomedics                      

9.Competitive Landscape                                            

                9.1 Market share analysis                            

                9.2 Merger and Acquisition Analysis                        

                9.3 Agreements, collaborations and Joint Ventures                          

                9.4 New Product Launches                          

10.Market Outlook and Investment Opportunities                                           

Appendix                                           

                a) List of Tables                

                b) List of Figures                              

  1. Middle East & Africa Cancer Immunotherapy Market, By Application, From 2022 - 2027 (USD Billion)
  2. Middle East & Africa Breast Market, By Region, From 2022 - 2027 (USD Billion)
  3. Middle East & Africa Lung Market, By Region, From 2022 - 2027 (USD Billion)
  4. Middle East & Africa Melanoma Market, By Region, From 2022 - 2027 (USD Billion)
  5. Middle East & Africa Colorectal Market, By Region, From 2022 - 2027 (USD Billion)
  6. Middle East & Africa Head & Neck Market, By Region, From 2022 - 2027 (USD Billion)
  7. Middle East & Africa Prostate Market, By Region, From 2022 - 2027 (USD Billion)
  8. Middle East & Africa Cancer Immunotherapy Market, By Product Type, From 2022 - 2027 (USD Billion)
  9. Middle East & Africa Monoclonal Antibodies Market, By Region, From 2022 - 2027 (USD Billion)
  10. Middle East & Africa Checkpoint inhibitors/immune modulators Market, By Region, From 2022 - 2027 (USD Billion)
  11. Middle East & Africa Therapeutic cancer vaccines Market, By Region, From 2022 - 2027 (USD Billion)
  12. Middle East & Africa Oncolytic virus immunotherapy Market, By Region, From 2022 - 2027 (USD Billion)
  13. Middle East & Africa Cytokines Market, By Region, From 2022 - 2027 (USD Billion)
  14. Middle East & Africa Adoptive T cell Transfer Market, By Region, From 2022 - 2027 (USD Billion)
  15. Middle East & Africa Adjuvant immunotherapy Market, By Region, From 2022 - 2027 (USD Billion)
  16. Middle East & Africa Interferons Market, By Region, From 2022 - 2027 (USD Billion)
  17. Middle East & Africa Interleukins Market, By Region, From 2022 - 2027 (USD Billion)
  18. Middle East & Africa BCG Market, By Region, From 2022 - 2027 (USD Billion)
  19. Middle East & Africa Cancer Immunotherapy Market, By Mode of Administration, From 2022 - 2027 (USD Billion)
  20. Middle East & Africa Intravenous Market, By Region, From 2022 - 2027 (USD Billion)
  21. Middle East & Africa Oral Market, By Region, From 2022 - 2027 (USD Billion)
  22. Middle East & Africa Topical Market, By Region, From 2022 - 2027 (USD Billion)
  23. Middle East & Africa Intravesical Market, By Region, From 2022 - 2027 (USD Billion)
  24. Middle East & Africa Cancer Immunotherapy Market, By End users, From 2022 - 2027 (USD Billion)
  25. Middle East & Africa hospitals Market, By Region, From 2022 - 2027 (USD Billion)
  26. Middle East & Africa Clinics Market, By Region, From 2022 - 2027 (USD Billion)
  27. Middle East Cancer Immunotherapy Market, By Application, From 2022 - 2027 (USD Billion)
  28. Middle East Cancer Immunotherapy Market, By Product Type, From 2022 - 2027 (USD Billion)
  29. Middle East Cancer Immunotherapy Market, By Mode of Administration, From 2022 - 2027 (USD Billion)
  30. Middle East Cancer Immunotherapy Market, By End users, From 2022 - 2027 (USD Billion)
  31. Africa Cancer Immunotherapy Market, By Application, From 2022 - 2027 (USD Billion)
  32. Africa Cancer Immunotherapy Market, By Product Type, From 2022 - 2027 (USD Billion)
  33. Africa Cancer Immunotherapy Market, By Mode of Administration, From 2022 - 2027 (USD Billion)
  34. Africa Cancer Immunotherapy Market, By End users, From 2022 - 2027 (USD Billion)

Please wait. . . . Your request is being processed

Related Reports

PURCHASE OPTIONS

excel
$

2875


pdf excel
$

3220


pdf excel powerbi
$

4600


excel
$

2000

What You Get :

  • PDF Report Format.
  • Can be accessible by 1 single user.
  • 6 Months of Free Analyst Support.
  • PDF and Excel Datasheet Formats.
  • Can be accessible upto 2 to 5 users.
  • 1 Year of Free Analyst Support.
  • PDF, Excel and Power BI Dashboard.
  • Can be accessible by unlimited users.
  • 1 Year of Free Analyst Support.
  • Excel Datasheet Format.
  • Customized access as per user request.
  • Upgradable to other licenses.
customer-support
ASK FOR CUSTOMIZATION

Talk to our analyst and get customised report done according to your research needs

tag
INQUIRE FOR DISCOUNT

Check if you can avail any discount. Submit your details and our team will get back to you.

cloud-download
DOWNLOAD FREE SAMPLE

Request to avail a free sample report that reflects this market and its growth.

Access the study in MULTIPLE FORMATS
Purchase options starting from $ 2875

Didn’t find what you’re looking for?
TALK TO OUR TEAM

Find it too expensive?
NO WORRIES!

Click for Request Sample